Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition.
(2007) In European Journal of Heart Failure 9(2). p.191-196- Abstract
- Background: The beneficial effects of angiotensin converting enzyme (ACE)-inhibitors are in part mediated through the inhibition of the degradation of the vasodilator bradykinin. The bradykinin effect is counteracted by cyclooxygenase-inhibitors. Angiotensin receptor blockers (ARBs) do not affect bradykinin. Aims: To test the hypothesis that renal counteraction from a cyclooxygenase-inhibitor, diclofenac, is different in subjects treated with an ACE-inhibitor, enalapril compared with an ARB, losartan. Methods: Twelve elderly, healthy, slightly over-hydrated subjects received diclofenac orally after pre-treatment with a diuretic, bendroflumethiazide, and enalapril or bendroflumethiazide and losartan, in a double-blind cross-over fashion,... (More)
- Background: The beneficial effects of angiotensin converting enzyme (ACE)-inhibitors are in part mediated through the inhibition of the degradation of the vasodilator bradykinin. The bradykinin effect is counteracted by cyclooxygenase-inhibitors. Angiotensin receptor blockers (ARBs) do not affect bradykinin. Aims: To test the hypothesis that renal counteraction from a cyclooxygenase-inhibitor, diclofenac, is different in subjects treated with an ACE-inhibitor, enalapril compared with an ARB, losartan. Methods: Twelve elderly, healthy, slightly over-hydrated subjects received diclofenac orally after pre-treatment with a diuretic, bendroflumethiazide, and enalapril or bendroflumethiazide and losartan, in a double-blind cross-over fashion, with a wash-out period of at least 1 week. Results: Diclofenac reduced GFR significantly from 81(64-98) ml/min at first observations after dose for enalapril to 29(16-42) and from 76 (64-88) afler losartan to 35(24-46). There was no significant difference between enalapril and losartan in GFR. Diclofenac induced decreases in urine flow, excretion rates and clearances of sodium, osmolality clearance and free water clearance, irrespective of treatment with enalapril or losartan. However, serum potassium and handling of potassium were significantly lower after losartan-treatment. Conclusion: The negative renal effects of diclofenac administration in subjects with activation of the renin-angiotensin system and enalapril treatment are the same in subjects with activation of the renin-angiotensin system and losartan treatment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/158865
- author
- Juhlin, Tord LU ; Erhardt, Leif RW LU ; Ottosson, Helene LU ; Jönsson, Bo A LU and Höglund, Peter LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Journal of Heart Failure
- volume
- 9
- issue
- 2
- pages
- 191 - 196
- publisher
- Elsevier
- external identifiers
-
- wos:000245310700016
- scopus:33847794819
- ISSN
- 1879-0844
- DOI
- 10.1016/j.ejheart.2006.05.015
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Cardiology (013242100), Division of Occupational and Environmental Medicine (013078001), Division of Clinical Chemistry and Pharmacology (013250300), Cardiology Research Group (013242120), Emergency medicine/Medicine/Surgery (013240200)
- id
- 3f3ebba0-5125-4fd3-8565-1f9361ce5a29 (old id 158865)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16859993&dopt=Abstract
- date added to LUP
- 2016-04-01 11:44:57
- date last changed
- 2022-01-26 17:39:57
@article{3f3ebba0-5125-4fd3-8565-1f9361ce5a29, abstract = {{Background: The beneficial effects of angiotensin converting enzyme (ACE)-inhibitors are in part mediated through the inhibition of the degradation of the vasodilator bradykinin. The bradykinin effect is counteracted by cyclooxygenase-inhibitors. Angiotensin receptor blockers (ARBs) do not affect bradykinin. Aims: To test the hypothesis that renal counteraction from a cyclooxygenase-inhibitor, diclofenac, is different in subjects treated with an ACE-inhibitor, enalapril compared with an ARB, losartan. Methods: Twelve elderly, healthy, slightly over-hydrated subjects received diclofenac orally after pre-treatment with a diuretic, bendroflumethiazide, and enalapril or bendroflumethiazide and losartan, in a double-blind cross-over fashion, with a wash-out period of at least 1 week. Results: Diclofenac reduced GFR significantly from 81(64-98) ml/min at first observations after dose for enalapril to 29(16-42) and from 76 (64-88) afler losartan to 35(24-46). There was no significant difference between enalapril and losartan in GFR. Diclofenac induced decreases in urine flow, excretion rates and clearances of sodium, osmolality clearance and free water clearance, irrespective of treatment with enalapril or losartan. However, serum potassium and handling of potassium were significantly lower after losartan-treatment. Conclusion: The negative renal effects of diclofenac administration in subjects with activation of the renin-angiotensin system and enalapril treatment are the same in subjects with activation of the renin-angiotensin system and losartan treatment.}}, author = {{Juhlin, Tord and Erhardt, Leif RW and Ottosson, Helene and Jönsson, Bo A and Höglund, Peter}}, issn = {{1879-0844}}, language = {{eng}}, number = {{2}}, pages = {{191--196}}, publisher = {{Elsevier}}, series = {{European Journal of Heart Failure}}, title = {{Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition.}}, url = {{http://dx.doi.org/10.1016/j.ejheart.2006.05.015}}, doi = {{10.1016/j.ejheart.2006.05.015}}, volume = {{9}}, year = {{2007}}, }